- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04308434
CSD190601: A Study to Determine Subject Puffing Patterns of Electronic Nicotine Delivery Systems in an Ambulatory Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Potential subjects may complete a pre-screening interview (by phone) and will complete a Screening Visit to assess their eligibility. Based on meeting eligibility requirements, it is desirable that subjects will be enrolled into the study on the same day of their Screening Visit. However, because of delays in receiving clinical laboratory test results, additional time may be needed to complete Enrollment. It may be necessary that subjects will need to return to the clinic on another day to compete Enrollment.
To minimize bias, subjects will be assigned to either Product A or Product B based on the scheduled visit to the clinic during Screening and Enrollment. Subjects will then be assigned to one of the seven e-liquid flavor variants for either Product A or Product B. Subjects will be allowed to sample or try flavors and determine which flavor that they would like to use for the length of the study.
At the Screening/Enrollment visit, subjects will be provided an orientation to the product, including the power unit and cartridges for their assigned product, and the corresponding Product Use and Behavior (PUB) instrument, PUB application, and an electronic device provided by the Sponsor. Based upon their UB ENDS usage, they will be given a sufficient amount (for three weeks of ad libitum use equaling 375% of their self-reported UB reported weekly use) of their assigned Product A or Product B cartridges.
The study will involve a one-week acclimation period followed by a two-week product use evaluation period. Subjects will be instructed to use their assigned Product A or Product B product in place of their UB ENDS during the three-week study period, but they will be allowed to use non-ENDS tobacco/nicotine-containing products according to their normal use pattern. The PUB instrument will collect topography data, and product use data will be uploaded frequently using a web-based PUB application installed on the electronic device provided by the Sponsor.
At the end of the first week of the study, subjects will receive a phone call from the clinic to assess Investigational Product (IP) compliance and to ensure that they are not using their UB ENDS. Throughout the study, subjects will receive weekly phone calls at a minimum to remind them of guidelines for using their assigned IP. All used cartridges may be disposed of by the subject.
At the conclusion of the three-week ambulatory period, the subjects will return to the clinic, return the Product A or Product B power unit, any associated USB charger, all unused IP cartridges, the corresponding PUB instrument and its charger, and the provided electronic device. Each subject will complete all End of Study procedures including completing the Product Evaluation Scale (PES) questionnaire, and then subjects will be discharged from the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Stockbridge, Georgia, United States, 30281
- Clinical Research Atlanta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.
- Generally healthy male or female, ≥ 21 years of age, inclusive, at the time of consent.
- Positive urine cotinine test at Screening.
- Cartridge-based, closed-system ENDS are the primary form of tobacco/nicotine-containing products used within 30 days of Screening. Subjects may be users of other tobacco/nicotine-containing products. If the subject is a dual/poly user of tobacco/nicotine-containing products then the subject must self report that a cartridge-based, closed-system ENDS is their primary product.
- Must have used 2 or more cartridges per week over the last 30 days. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Principal Investigator (PI).
- Females must be willing to use a form of contraception acceptable to the PI from the time of signing the ICF until the end of the study.
- Must be willing to use the assigned IP and only the assigned flavor as their exclusive source of ENDS use for the full duration of the three-week ambulatory period. Use of other non-ENDS tobacco/nicotine-containing products will be permitted during the ambulatory period.
- Must have familiarity with modern electronic devices such as an IOS/Android smart phone or tablet computer ("tablet") and be willing to be provided an electronic device, that allows for both Bluetooth connectivity and internet connectivity and be willing to keep both active for the length of the study.
- Must be willing to use an application on the provided electronic device, and keep the application active for the length of the study.
Exclusion Criteria:
- Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.
- History or presence of diabetes.
- Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for five minutes, with exceptions at the PI's discretion.
- Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening-Enrollment Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion pending approval from the Medical Monitor.
- Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
- Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT, e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to the signing of informed consent.
- Participation in another clinical trial within (≤) 30 days prior to signing the ICF. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
- A positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening.
- Postpones a decision to quit using tobacco/ nicotine-containing products in order to participate in this study or a previous attempt within (≤) 30 days prior to the signing of the ICF.
- Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol breathalyzer result at Screening.
- Determined by the PI to be inappropriate for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CSD190601-11
Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-12
Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-13
Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-14
Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-15
Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-16
Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-17
Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
|
Experimental: CSD190601-21
Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-22
Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-23
Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-24
Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
|
Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-25
Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-26
Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
|
Experimental: CSD190601-27
Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
|
Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arithmetic Mean
Time Frame: 2 weeks
|
Arithmetic Mean puff duration
|
2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CSD190601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on CSD190601-11
-
Universität des SaarlandesFIFA-Medical Assessment and Research Centre (F-MARC), Zurich, SwitzerlandCompleted
-
Mayo ClinicEnrolling by invitationParkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic AphasiaUnited States
-
Margaret RagniWyeth is now a wholly owned subsidiary of Pfizer; University of North CarolinaCompletedVon Willebrand DiseaseUnited States
-
University Hospital, GhentCompleted
-
NImmune BiopharmaWithdrawnEosinophilic Esophagitis
-
University of PittsburghCompletedHemophilia A | Von Willebrand DiseaseUnited States
-
Nihon Pharmaceutical Co., LtdCompletedStomach DiseasesJapan
-
NImmune BiopharmaCompletedUlcerative ColitisUnited States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Not yet recruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed